Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD

Last updated: October 27, 2025
Sponsor: Texas A&M University
Overall Status: Active - Recruiting

Phase

2

Condition

Alcohol Dependence

Alcohol Use Disorder

Addictions

Treatment

Cognitive Processing Therapy + Relapse Prevention

Relapse Prevention

Clinical Study ID

NCT05959434
IRB2023-0985 / 162260
R01AA030157
  • Ages 18-70
  • All Genders

Study Summary

The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD).

Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequency (percent days drinking) and quantity (drinks per drinking day) as measured by the Timeline Follow-Back (TLFB).

Specific Aim 2: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5).

Specific Aim 3: Use ecological momentary assessment (EMA) to evaluate intervention effects on daily alcohol-related cognitions and behaviors through real-time associations with PTSD symptomatology and distress tolerance.

Researchers will compare integrative CPT+RP with RP-alone to see if CPT+RP is more efficacious in reducing alcohol use and PTSD symptom severity.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Any gender identity, any race or ethnicity, aged 18-70 years.

  2. Able to provide written informed consent.

  3. Ability to understand English.

  4. Meet DSM-5 diagnostic criteria for current (past month) moderate to severe alcoholuse disorder ( >= 4 criteria).

  5. At least 3 to 4 heavy drinking days per week (4 or more drinks for a woman, 5 ormore drinks for a man) in the last 30 days, or >14 drinks per week for females or > 21 drinks per week for males for at least 2 weeks in the last 30 days.

  6. Meet DSM-5 diagnostic criteria for current (past month) PTSD as assessed by theCAPS-5.

  7. Participants may also meet criteria for a mood disorder (except bipolar affectivedisorder, see Exclusion Criteria) or anxiety disorders. The inclusion ofparticipants with affective and anxiety disorders is essential because of the markedfrequency of the co-existence of mood and anxiety disorders among patients with AUDand PTSD. Concurrent substance use disorders are acceptable provided alcohol is theparticipant's primary substance of choice.

  8. Participants taking psychotropic medications will be required to be maintained on astable dose for at least 4 weeks before study initiation.

Exclusion

Exclusion Criteria:

  1. Meeting DSM-5 criteria for a history of or current psychotic disorder or bipolardisorder, or imminent risk of suicidal or homicidal behavior. The intervention maybe insufficient, and those participants will be referred clinically for a higherlevel of care.

  2. Participants on psychotropic medications which have been initiated during the past 4weeks.

  3. Acute alcohol withdrawal as indicated by CIWA-Ar scores >8. Those participants willbe referred clinically for medically supervised detoxification. They may bere-evaluated for eligibility after detoxification.

  4. Pregnancy or breastfeeding for women.

  5. Currently enrolled in evidence-based behavioral treatment for AUD or PTSD.Attendance at therapeutic activities (e.g., Alcoholics Anonymous) other than studysessions will be closely monitored using the Treatment Services Review.

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: Cognitive Processing Therapy + Relapse Prevention
Phase: 2
Study Start date:
April 01, 2024
Estimated Completion Date:
July 31, 2028

Study Description

A substantial proportion of individuals with alcohol use disorder (AUD) also meet criteria for posttraumatic stress disorder (PTSD). The co-occurrence of AUD/PTSD is characterized by more severe symptomatology, greater functional impairment, increased suicide risk, and poorer treatment outcomes as compared to either disorder alone. Trauma-focused, cognitive-behavioral interventions delivered alongside interventions for substance use disorders are most effective in reducing PTSD severity and substance use. Cognitive Processing Therapy (CPT) for PTSD and Relapse Prevention (RP) for AUD are two of the most widely used and efficacious behavioral treatments for these conditions. The investigators successfully developed and pilot tested a therapy manual that combines CPT with RP. The preliminary data demonstrate safety, feasibility, high rates of retention (80.0%) and patient satisfaction. Moreover, our data from a recent national survey of frontline mental health providers indicate that CPT is the most commonly used trauma-focused treatment for PTSD and providers are highly interested in an integrative CPT-RP intervention, conferring strong potential for uptake in real-world practice settings. In fact, due to the lack of an available, empirically developed, manualized CPT-RP treatment, 84.0% of frontline providers report attempting on their own to create such a treatment to use with their patients. This may result in highly variable and suboptimal implementation and outcomes. In response to provider input and positive preliminary data, the proposed study directly addresses this critical need by evaluating a new integrative CPT-RP treatment for individuals with co-occurring AUD and PTSD. At present, only one trauma-focused, integrative intervention is available for AUD/PTSD and it uses Prolonged Exposure (PE) to reduce PTSD symptoms. In comparison to PE, CPT is more widely used, often preferred by clinicians, equally as effective in reducing PTSD symptoms, and associated with lower dropout rates. Thus, the new CPT-RP intervention could have wider reach and greater acceptability than exposure-based treatments. Treatment choice is related to improved treatment outcomes, and therefore, there is an immediate need to add to the portfolio of evidence-based, trauma-focused, integrative treatments for AUD/PTSD. The primary objective of this Stage II study is to examine the efficacy of CPT-RP, as compared to RP alone, in reducing (1) alcohol use frequency and quantity and (2) PTSD symptom severity among individuals with current AUD/PTSD. To accomplish this, a randomized study design, manualized intervention, and standardized repeated dependent measures of clinical outcomes at multiple time points will be employed. Putative mechanisms of behavior change will be evaluated via daily monitoring. The proposed study aligns closely with the mission of NIAAA in that it aims to produce maximally efficacious behavioral interventions for AUD and comorbid psychiatric disorders such as PTSD. The findings from this study will provide new information to advance the science of AUD/PTSD comorbidity and innovate clinical practice.

Connect with a study center

  • Medical University of South Carolina

    Charleston, South Carolina 29425
    United States

    Site Not Available

  • Medical University of South Carolina

    Charleston 4574324, South Carolina 4597040 29425
    United States

    Active - Recruiting

  • Texas A&M University

    College Station, Texas 77843
    United States

    Site Not Available

  • Texas A&M University

    College Station 4682464, Texas 4736286 77843
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.